1. Shares of GlaxoSmithKline India twins unfazed by hammering of GSK stock in London

Shares of GlaxoSmithKline India twins unfazed by hammering of GSK stock in London

GlaxoSmithKline Pharmaceuticals Ltd and GlaxoSmithKline Consumer Healthcare Ltd shares surged in trade today, unfazed by the rout in the shares of the companies’ parent corporation in the UK.

By: and | Updated: July 5, 2017 5:53 PM
Shares of GlaxoSmithKline Pharmaceuticals ended up 2.12% at Rs 2,580 on BSE today, while shares of GlaxoSmithKline Consumer Healthcare closed at Rs 5,500.1, up 1.85%. (Image: Reuters)

GlaxoSmithKline Pharmaceuticals Ltd and GlaxoSmithKline Consumer Healthcare Ltd shares surged in trade today, unfazed by the rout in the shares of the companies’ parent corporation in the UK. Shares of GlaxoSmithKline Pharmaceuticals ended up 2.12% at Rs 2,580 on BSE today, while shares of GlaxoSmithKline Consumer Healthcare closed at Rs 5,500.1, up 1.85%. On the other hand, GlaxoSmithKline Plc’s shares fell 1.5% to GBP 1604.07 in the early trade on London Stock Exchange today.

From Reuters:

The threat of new competition and potential loss of market share in GlaxoSmithKline’s flagship HIV drug business have unnerved investors in Britain’s biggest drugmaker. GSK was the biggest loser in London’s FTSE-100 index after Citigroup downgraded the stock to neutral from buy and cut earnings forecasts by up to 9%.

HIV medicines, which GSK sells through its ViiV Healthcare unit, have been star performers in its pharma business in recent years and GSK plans to defend its patch with a new two-drug treatment regimen for controlling the virus behind AIDS. But arch-rival Gilead Sciences is developing a rival three-in-one daily pill and Merck & Co also has a novel medicine that could challenge both.

Citi analyst Andrew Baum said Merck could, in fact, end up beating both GSK and Gilead with its new drug EFdA, which may reach the market as early as 2021 and has the potential to be developed as both a daily pill and a twice-yearly injection. Given the early nature of Merck’s experimental product, Citi currently forecasts heavily risk-adjusted peak annual sales of $150 million for EFdA but it believes commercial success could add more than $5 billion to forecasts.

GSK’s HIV drug dolutegravir, which is used in the medicines Tivicay and Triumeq, has been the mainstay of the British group’s HIV operation and investors are nervous about any threat to what is a highly profitable business. Antiretroviral therapy has turned HIV from a death sentence into a manageable condition but patients need to stay on treatment for life, so there is a growing focus on making medication as convenient and well-tolerated as possible.

  1. No Comments.

Go to Top